Please use this identifier to cite or link to this item:
|Title:||Skin adverse events in recently approved targeted therapies in solid malignancies||Authors:||Habre, Maya
Habre, Samer Bassilios
Abi Chebl, Joanna
Kourie, Hampig Raphael
|Affiliations:||Faculty of Medicine
Faculty of Medicine
Tyrosine kinase inhibitors
|Issue Date:||2019||Part of:||Future Oncology||Volume:||15||Issue:||3||Start page:||331||End page:||343||Abstract:||
Targeted anticancer therapies are an important weapon in the fight against cancer. Targeted therapies interfere with specific molecules necessary for tumor growth and cancer progression. They are divided mainly to either monoclonal antibodies or small molecules inhibitors. Their primary objective is to target directly and precisely the cancer cells leading to a minimal side-effects profile. The dermatologic adverse reactions of these targeted therapies is different from those seen with classical cytotoxic chemotherapy. Rashes, xerosis, hand-foot-skin reaction and mucositis are the most frequent side effects. In this paper, we aim to present a comprehensive review of the dermatologic side effects of targeted therapies including, specific side effects related to recently, approved targeted therapies.
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Aug 13, 2022
checked on Aug 14, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.